Journal article
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Abstract
BACKGROUND: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.
METHODS: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18-85 years with type 2 …
Authors
Heerspink HJL; Parving H-H; Andress DL; Bakris G; Correa-Rotter R; Hou F-F; Kitzman DW; Kohan D; Makino H; McMurray JJV
Journal
The Lancet, Vol. 393, No. 10184, pp. 1937–1947
Publisher
Elsevier
Publication Date
May 2019
DOI
10.1016/s0140-6736(19)30772-x
ISSN
0140-6736